MetaCap

Intercure (INCR) vs Spero Therapeutics (SPRO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Intercure (INCR) has outperformed Spero Therapeutics (SPRO) over the past year, losing 50.6% versus a loss of 67.9%. Over five years, INCR leads with a -90.9% price change compared with -95.1% for SPRO. Spero Therapeutics is the larger company by market cap ($43.2 million vs $42.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

INCR-50.57%SPRO-67.88%
+34%-19%-73%
Nov 21, 20251 yearNov 20, 2026
INCR-91.77%SPRO-95.50%
+9%-46%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

INCR versus SPRO key metrics
MetricINCRSPRO
Share price$3.24$0.742
Market cap$42.03M$43.23M
1-day change-7.69%-10.20%
YTD return-28.79%-68.15%
1-year return-50.57%-67.88%
5-year return-90.87%-95.09%
EPS (TTM)$-0.95$-0.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$66.80M
Revenue growth (YoY)—+39.24%
Net income (latest FY)—$8.57M
Operating margin—9.45%
Net margin—12.83%
52-week high$7.55$3.08
52-week low$3.12$0.73
Distance from 52-week high-57.09%-75.91%
Analyst consensus—none
Avg. price target upside—+573.85%
Average volume15.93K530.46K
Shares outstanding12.97M58.26M
Employees28525
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INCR has outperformed SPRO by 17.3 percentage points over the past year.

About Intercure

INCR stock →

InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.

Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees

About Spero Therapeutics

SPRO stock →

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

INCR vs SPRO FAQ

Which is bigger, Intercure or Spero Therapeutics?

Spero Therapeutics (SPRO) is larger, with a market capitalization of $43.23M compared with $42.03M for Intercure (INCR).

Which stock has performed better over the past year, INCR or SPRO?

INCR returned -50.57% over the past 12 months, compared with -67.88% for SPRO (price return, excluding dividends). Past performance does not predict future results.

Are Intercure and Spero Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons